Accuray (ARAY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting will be held virtually on November 21, 2024, with voting on key proposals including director elections, amendments to equity and stock purchase plans, executive compensation, and auditor ratification.
Only shareholders of record as of September 23, 2024, are entitled to vote, with 100,273,770 shares outstanding, each entitled to one vote per item.
The board recommends voting in favor of all proposals, and shareholders can vote online, by phone, or by mail.
Voting matters and shareholder proposals
Election of two Class III directors to serve until 2027.
Approval of amendments to the 2016 Equity Incentive Plan (increase by 5,000,000 shares) and 2007 Employee Stock Purchase Plan (increase by 2,500,000 shares).
Advisory vote on executive compensation (say-on-pay).
Ratification of Grant Thornton LLP as independent auditor for fiscal year ending June 30, 2025.
No other shareholder proposals or business are anticipated.
Board of directors and corporate governance
Board consists of eight directors, with a mix of industry, financial, and leadership experience; four women and four men, meeting Nasdaq diversity objectives.
Board committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.
Majority voting standard for director elections; directors submit contingent resignations if not elected by majority.
Board leadership is separated between Chairperson and CEO.
Latest events from Accuray
- Shelf registration covers resale of 7M shares from warrants tied to recent financing.ARAY
Registration Filing17 Feb 2026 - Revenue and margin guidance cut as China headwinds, tariffs, and financing changes weigh.ARAY
Q2 202617 Feb 2026 - Record Q4 revenue and robust FY25 outlook highlight strong growth and global expansion.ARAY
Q4 20241 Feb 2026 - Growth driven by innovation, emerging markets, and margin expansion, with U.S. recovery expected.ARAY
Jefferies Global Healthcare Conference31 Jan 2026 - FY2025 guidance raised as China growth and service gains offset margin and revenue declines.ARAY
Q1 202516 Jan 2026 - Q3 FY25 revenue up 12%, net loss narrowed, but guidance cut on tariffs; EBITDA improved.ARAY
Q3 202527 Dec 2025 - Q2 revenue up 8% to $116.2M, net income $2.5M, margin 36.1%, guidance raised.ARAY
Q2 202524 Dec 2025 - Resale registration covers 23.4M shares from warrant exercises tied to recent financing.ARAY
Registration Filing16 Dec 2025 - Major leadership changes and transformation plan target growth, margin expansion, and agility.ARAY
Proxy Filing1 Dec 2025